Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps
The Journal of Allergy and Clinical Immunology: In Practice · 2023
DOI: 10.1016/j.jaip.2023.08.015 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023. Verfasst von Geoffrey Chupp und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale School of Medicine, New Haven, Conn. Electronic address: geoffrey.chupp@yale.edu. Hauptthemen laut MEDLINE: Nasal Polyps, Rhinitis, Sinusitis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline.
Abstract (Originalsprache)
BACKGROUND: Systemic corticosteroids (SCSs) are associated with short- and long-term adverse effects. OBJECTIVE: To assess mepolizumab efficacy according to prior SCS use and characterize mepolizumab's SCS-sparing capabilities, in patients with severe chronic rhinosinusitis with nasal polyps. METHODS: In the randomized, double-blind, phase III SYNAPSE trial (NCT03085797), adults with severe chronic rhinosinusitis with nasal polyps eligible for repeat sinus surgery despite standard of care treatment received mepolizumab (100 mg subcutaneously) or placebo every 4 weeks for 52 weeks. The impact of prior SCS courses (0/1/>1) on mepolizumab versus placebo treatment responses (changes from baseline in total endoscopic nasal polyp [week 52], nasal obstruction visual analog scale [weeks 49-52], and 22-item Sino-Nasal Outcome Test total [week 52] scores) was analyzed post hoc. To characterize mepolizumab's SCS-sparing capabilities, time-to-first SCS course for nasal polyps (prespecified) and total prednisolone-equivalent oral corticosteroid dose by patient baseline characteristics (post hoc, in patients with ≥1 SCS course during SYNAPSE) were assessed up to week 52. RESULTS: Mepolizumab versus placebo improved treatment responses, irrespective of prior SCS use. By week 52, the probability of requiring SCSs for nasal polyps (Kaplan-Meier estimate [95% CI]) was lower with mepolizumab (25.4% [20.0-32.1]) versus placebo (37.5% [31.1-44.6]). In patients requiring 1 or more dose of SCSs, total (mean ± SD mg/y) prednisolone-equivalent oral corticosteroid dose was lower with mepolizumab (438.9 ± 350.40) versus placebo (505.2 ± 455.091), overall and irrespective of prior sinus surgeries, blood eosinophil count, or comorbidities. CONCLUSIONS: Mepolizumab is associated with clinical benefits in patients with severe chronic rhinosinusitis with nasal polyps regardless of prior SCS use and has an SCS-sparing effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Yale School of Medicine, New Haven, Conn. Electronic address: geoffrey.chupp@yale.edu.
- Department of Otorhinolaryngology, Universitat de Barcelona, Barcelona, Spain; Institut d Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigacion Biomedica en Red de Enfermedad…
- Department of Medicine, University of Michigan, Ann Arbor, Mich.
- Royal National ENT Hospital, UCLH London, London, United Kingdom.
- Departement de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, CHU Montpellier, Montpellier, France; University of Montpellier, Montpellier, France.
- Technical University of Munich, TUM School of Medicine, Klinikum rechts der Isar, Department of Otolaryngology and Center for Allergy and Environment, Munich, Germany.
Förderung
- GlaxoSmithKline
Zitieren
APA
Chupp, G., Alobid, I., Lugogo, N. L., Kariyawasam, H. H., Bourdin, A., Chaker, A. M., Smith, S. G., Sousa, A. R., Mayer, B., Chan, R. H., & Matucci, A. (2023). Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2023.08.015
Vancouver
Chupp G, Alobid I, Lugogo NL, Kariyawasam HH, Bourdin A, Chaker AM, et al. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps. The Journal of Allergy and Clinical Immunology: In Practice. 2023. doi:10.1016/j.jaip.2023.08.015
BibTeX
@article{Chupp2023,
author = {Chupp, Geoffrey and Alobid, Isam and Lugogo, Njira L and Kariyawasam, Harsha H and Bourdin, Arnaud and Chaker, Adam M and Smith, Steven G and Sousa, Ana R and Mayer, Bhabita and Chan, Robert H and Matucci, Andrea},
title = {Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2023},
doi = {10.1016/j.jaip.2023.08.015}
}
EUVIMED